HK1203949A1 - 抑制劑 - Google Patents

抑制劑

Info

Publication number: HK1203949A1
Authority: HK; Hong Kong
Prior art keywords: iap; inhibitors; iap iap
Prior art date: 2012-01-03

Application number

HK15104538.4A

Other languages

English (en)

Inventor

‧科昂

‧加扎德

‧徐

‧弗吕加勒

Original Assignee

Curisinc

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-01-03

Filing date

2015-05-13

Publication date

2015-11-06

2015-05-13 Application filed by Curisinc, Genentech Inc filed Critical Curisinc

2015-11-06 Publication of HK1203949A1 publication Critical patent/HK1203949A1/zh

Links

239000003112 inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Thiazole And Isothizaole Compounds (AREA)

HK15104538.4A 2012-01-03 2015-05-13 抑制劑 HK1203949A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261582760P	2012-01-03	2012-01-03
PCT/US2013/020124 WO2013103703A1 (en)	2012-01-03	2013-01-03	Inhibitors of iap

Publications (1)

Publication Number	Publication Date
HK1203949A1 true HK1203949A1 (zh)	2015-11-06

Family

ID=48695302

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15104538.4A HK1203949A1 (zh)	2012-01-03	2015-05-13	抑制劑

Country Status (41)

Country	Link
US (6)	US8716236B2 (zh)
EP (2)	EP2800749B1 (zh)
JP (2)	JP5747137B2 (zh)
KR (3)	KR101855566B1 (zh)
CN (2)	CN107915728B (zh)
AR (2)	AR089623A1 (zh)
AU (1)	AU2013202780B2 (zh)
BR (1)	BR112014016637B1 (zh)
CA (1)	CA2861637C (zh)
CL (1)	CL2014001770A1 (zh)
CO (1)	CO7020915A2 (zh)
CR (1)	CR20140367A (zh)
CY (2)	CY1118371T1 (zh)
DK (2)	DK3133073T3 (zh)
EC (1)	ECSP14011792A (zh)
ES (2)	ES2594856T3 (zh)
HK (1)	HK1203949A1 (zh)
HR (2)	HRP20161381T1 (zh)
HU (2)	HUE037760T2 (zh)
IL (2)	IL233386A (zh)
LT (2)	LT3133073T (zh)
MA (1)	MA35895B1 (zh)
ME (2)	ME03084B (zh)
MX (1)	MX336294B (zh)
MY (1)	MY178390A (zh)
NO (1)	NO2755614T3 (zh)
NZ (1)	NZ627480A (zh)
PE (1)	PE20142182A1 (zh)
PH (2)	PH12014501534A1 (zh)
PL (2)	PL2800749T3 (zh)
PT (2)	PT2800749T (zh)
RS (2)	RS55327B1 (zh)
RU (2)	RU2728789C2 (zh)
SG (1)	SG11201403784QA (zh)
SI (2)	SI3133073T1 (zh)
SM (1)	SMT201600357B (zh)
TR (1)	TR201808088T4 (zh)
TW (1)	TWI503318B (zh)
UA (1)	UA114417C2 (zh)
WO (1)	WO2013103703A1 (zh)
ZA (1)	ZA201405535B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO2755614T3 (zh) *	2012-01-03	2018-03-31
WO2016079527A1 (en)	2014-11-19	2016-05-26	Tetralogic Birinapant Uk Ltd	Combination therapy
WO2016097773A1 (en)	2014-12-19	2016-06-23	Children's Cancer Institute	Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) *	2017-10-25	2022-04-29	广东东阳光药业有限公司	Iap抑制剂及其在药物中的应用
JP7257397B2 (ja)	2017-11-13	2023-04-13	チアタイティエンチンファーマシューティカルグループカンパニーリミテッド	Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途
JPWO2020027225A1 (ja)	2018-07-31	2021-11-11	ファイメクス株式会社	複素環化合物
US20220402935A1 (en)	2019-07-31	2022-12-22	Fimecs, Inc.	Heterocyclic compound
TW202133842A (zh) *	2019-12-02	2021-09-16	大陸商蘇州亞盛藥業有限公司	Iap抑制劑與parp或mek抑制劑或其他化學治療劑的組合
US20230056604A1 (en)	2020-01-20	2023-02-23	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20230233691A1 (en)	2021-10-22	2023-07-27	University Of Houston System	Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4526988A (en)	1983-03-10	1985-07-02	Eli Lilly And Company	Difluoro antivirals and intermediate therefor
WO1998046576A2 (en)	1997-04-15	1998-10-22	Genentech, Inc.	Halo-alkoxycarbonyl prodrugs
DK1778718T3 (da)	2004-07-02	2014-11-10	Genentech Inc	Iap-inhibitorer
DE602005022936D1 (de) *	2004-12-20	2010-09-23	Genentech Inc	Pyrrolidine als inhibitoren von iap
RU2009117701A (ru)	2006-10-12	2010-11-20	Новартис АГ (CH)	Производные пирролидина в качестве ингибиторов iap
PE20130150A1 (es)	2007-04-30	2013-02-27	Genentech Inc	Inhibidores de las iap
NO2755614T3 (zh)	2012-01-03	2018-03-31
USD690416S1 (en)	2012-12-12	2013-09-24	Pharmajet, Inc.	Needle-free syringe

2012
- 2012-09-13 NO NO12832667A patent/NO2755614T3/no unknown
2013
- 2013-01-02 AR ARP130100006A patent/AR089623A1/es not_active Application Discontinuation
- 2013-01-03 ES ES13733613.7T patent/ES2594856T3/es active Active
- 2013-01-03 LT LTEP16189661.8T patent/LT3133073T/lt unknown
- 2013-01-03 SG SG11201403784QA patent/SG11201403784QA/en unknown
- 2013-01-03 US US13/733,244 patent/US8716236B2/en active Active
- 2013-01-03 ES ES16189661.8T patent/ES2672809T3/es active Active
- 2013-01-03 RS RS20160910A patent/RS55327B1/sr unknown
- 2013-01-03 PT PT137336137T patent/PT2800749T/pt unknown
- 2013-01-03 SI SI201331047T patent/SI3133073T1/en unknown
- 2013-01-03 EP EP13733613.7A patent/EP2800749B1/en active Active
- 2013-01-03 CN CN201711212712.XA patent/CN107915728B/zh active Active
- 2013-01-03 BR BR112014016637-4A patent/BR112014016637B1/pt active IP Right Grant
- 2013-01-03 TW TW102100188A patent/TWI503318B/zh active
- 2013-01-03 KR KR1020157014670A patent/KR101855566B1/ko active IP Right Grant
- 2013-01-03 PL PL13733613T patent/PL2800749T3/pl unknown
- 2013-01-03 CA CA2861637A patent/CA2861637C/en active Active
- 2013-01-03 CN CN201380012308.1A patent/CN104159897A/zh active Pending
- 2013-01-03 MX MX2014007895A patent/MX336294B/es unknown
- 2013-01-03 DK DK16189661.8T patent/DK3133073T3/en active
- 2013-01-03 PL PL16189661T patent/PL3133073T3/pl unknown
- 2013-01-03 TR TR2018/08088T patent/TR201808088T4/tr unknown
- 2013-01-03 PT PT161896618T patent/PT3133073T/pt unknown
- 2013-01-03 MY MYPI2014001966A patent/MY178390A/en unknown
- 2013-01-03 SI SI201330343A patent/SI2800749T1/sl unknown
- 2013-01-03 RU RU2016124658A patent/RU2728789C2/ru active
- 2013-01-03 ME MEP-2018-161A patent/ME03084B/me unknown
- 2013-01-03 JP JP2014551313A patent/JP5747137B2/ja active Active
- 2013-01-03 HU HUE16189661A patent/HUE037760T2/hu unknown
- 2013-01-03 LT LTEP13733613.7T patent/LT2800749T/lt unknown
- 2013-01-03 ME MEP-2016-235A patent/ME02526B/me unknown
- 2013-01-03 KR KR1020187012124A patent/KR101917992B1/ko active IP Right Grant
- 2013-01-03 AU AU2013202780A patent/AU2013202780B2/en active Active
- 2013-01-03 RU RU2014130171/04A patent/RU2593259C2/ru active
- 2013-01-03 RS RS20180755A patent/RS57438B1/sr unknown
- 2013-01-03 EP EP16189661.8A patent/EP3133073B1/en active Active
- 2013-01-03 HU HUE13733613A patent/HUE031305T2/hu unknown
- 2013-01-03 WO PCT/US2013/020124 patent/WO2013103703A1/en active Application Filing
- 2013-01-03 DK DK13733613.7T patent/DK2800749T3/en active
- 2013-01-03 UA UAA201408260A patent/UA114417C2/uk unknown
- 2013-01-03 KR KR1020147021597A patent/KR101553792B1/ko active IP Right Grant
- 2013-01-03 NZ NZ627480A patent/NZ627480A/en unknown
- 2013-01-03 PE PE2014001069A patent/PE20142182A1/es active IP Right Grant
2014
- 2014-05-05 US US14/269,739 patent/US9238675B2/en active Active
- 2014-06-26 IL IL233386A patent/IL233386A/en active IP Right Grant
- 2014-06-26 IL IL242314A patent/IL242314A/en active IP Right Grant
- 2014-07-01 CL CL2014001770A patent/CL2014001770A1/es unknown
- 2014-07-02 PH PH12014501534A patent/PH12014501534A1/en unknown
- 2014-07-25 ZA ZA2014/05535A patent/ZA201405535B/en unknown
- 2014-07-25 CO CO14161919A patent/CO7020915A2/es unknown
- 2014-07-31 EC ECIEPI201411792A patent/ECSP14011792A/es unknown
- 2014-07-31 CR CR20140367A patent/CR20140367A/es not_active Application Discontinuation
- 2014-08-03 MA MA37254A patent/MA35895B1/fr unknown
2015
- 2015-05-08 PH PH12015501038A patent/PH12015501038A1/en unknown
- 2015-05-11 JP JP2015096425A patent/JP2015199738A/ja active Pending
- 2015-05-13 HK HK15104538.4A patent/HK1203949A1/zh unknown
- 2015-12-18 US US14/974,140 patent/US9586991B2/en active Active
2016
- 2016-10-06 SM SM201600357T patent/SMT201600357B/it unknown
- 2016-10-25 HR HRP20161381TT patent/HRP20161381T1/hr unknown
- 2016-12-07 CY CY20161101257T patent/CY1118371T1/el unknown
2017
- 2017-01-31 US US15/420,817 patent/US20170136084A1/en not_active Abandoned
2018
- 2018-06-22 CY CY20181100652T patent/CY1120355T1/el unknown
- 2018-06-26 HR HRP20180976TT patent/HRP20180976T1/hr unknown
2019
- 2019-04-02 US US16/372,940 patent/US11096982B2/en active Active
2021
- 2021-08-03 US US17/392,724 patent/US11963994B2/en active Active
- 2021-09-17 AR ARP210102590A patent/AR123542A2/es unknown

Also Published As

Publication number	Publication date
RU2593259C2 (ru)	2016-08-10
ECSP14011792A (es)	2015-12-31
BR112014016637A2 (pt)	2017-06-13
US20170136084A1 (en)	2017-05-18
NO2755614T3 (zh)	2018-03-31
PH12015501038B1 (en)	2015-09-21
TWI503318B (zh)	2015-10-11
MX2014007895A (es)	2015-03-19
PH12014501534B1 (en)	2014-10-08
JP2015199738A (ja)	2015-11-12
US20160102119A1 (en)	2016-04-14
SI3133073T1 (en)	2018-06-29
AR089623A1 (es)	2014-09-03
RU2016124658A (ru)	2018-12-04
IL242314A (en)	2016-08-31
RU2728789C2 (ru)	2020-07-31
US20140235551A1 (en)	2014-08-21
RS55327B1 (sr)	2017-03-31
KR20140107670A (ko)	2014-09-04
UA114417C2 (uk)	2017-06-12
CA2861637C (en)	2017-07-18
HRP20180976T1 (hr)	2018-08-10
CO7020915A2 (es)	2014-08-11
US20190224269A1 (en)	2019-07-25
JP5747137B2 (ja)	2015-07-08
PT2800749T (pt)	2016-10-24
ZA201405535B (en)	2017-08-30
RU2016124658A3 (zh)	2019-09-09
LT3133073T (lt)	2018-06-25
US9238675B2 (en)	2016-01-19
KR101553792B1 (ko)	2015-09-16
CN104159897A (zh)	2014-11-19
EP3133073A2 (en)	2017-02-22
JP2015504072A (ja)	2015-02-05
US9586991B2 (en)	2017-03-07
SMT201600357B (it)	2016-11-10
AU2013202780B2 (en)	2015-04-16
ME03084B (me)	2019-01-20
PL3133073T3 (pl)	2018-09-28
CR20140367A (es)	2015-02-18
AU2013202780A1 (en)	2013-07-18
SI2800749T1 (sl)	2016-11-30
CN107915728A (zh)	2018-04-17
MX336294B (es)	2016-01-14
HRP20161381T1 (hr)	2016-12-02
EP3133073A3 (en)	2017-03-22
HUE031305T2 (hu)	2017-07-28
SG11201403784QA (en)	2014-08-28
ME02526B (me)	2017-02-20
BR112014016637B1 (pt)	2022-06-14
RS57438B1 (sr)	2018-09-28
ES2672809T3 (es)	2018-06-18
US11963994B2 (en)	2024-04-23
MY178390A (en)	2020-10-12
KR101917992B1 (ko)	2018-11-13
DK2800749T3 (en)	2016-11-07
PL2800749T3 (pl)	2017-01-31
US20220211797A1 (en)	2022-07-07
ES2594856T3 (es)	2016-12-23
EP2800749B1 (en)	2016-09-21
CY1118371T1 (el)	2017-06-28
CY1120355T1 (el)	2019-07-10
CA2861637A1 (en)	2013-07-11
DK3133073T3 (en)	2018-06-18
AR123542A2 (es)	2022-12-14
US8716236B2 (en)	2014-05-06
KR20150065960A (ko)	2015-06-15
EP2800749A4 (en)	2015-08-05
HUE037760T2 (hu)	2018-09-28
US11096982B2 (en)	2021-08-24
CL2014001770A1 (es)	2015-04-17
BR112014016637A8 (pt)	2017-07-04
KR20180051646A (ko)	2018-05-16
CN107915728B (zh)	2021-04-30
EP2800749A1 (en)	2014-11-12
EP3133073B1 (en)	2018-05-02
PE20142182A1 (es)	2015-01-16
TW201333001A (zh)	2013-08-16
RU2014130171A (ru)	2016-02-27
TR201808088T4 (tr)	2018-06-21
LT2800749T (lt)	2016-10-25
IL233386A0 (en)	2014-08-31
KR101855566B1 (ko)	2018-05-04
PT3133073T (pt)	2018-06-18
US20130172264A1 (en)	2013-07-04
PH12014501534A1 (en)	2014-10-08
WO2013103703A1 (en)	2013-07-11
MA35895B1 (fr)	2014-12-01
IL233386A (en)	2016-08-31
NZ627480A (en)	2016-04-29
PH12015501038A1 (en)	2015-09-21

Publication	Publication Date	Title
PL2920149T3 (pl)	2019-11-29	Związki 3-aminocykloalkilowe jako inhibitory ror-gamma-t oraz ich zastosowania
AP4029A (en)	2017-02-05	Inhibitors of beta-secretase
HK1203949A1 (zh)	2015-11-06	抑制劑
HK1211024A1 (zh)	2016-05-13	的抑制劑
HK1209422A1 (zh)	2016-04-01	抑制劑
IL236963A0 (en)	2015-03-31	beta-secretase inhibitors
IL240763A0 (en)	2015-10-29	The halopyrazoles as thrombin inhibitors
PL2888228T3 (pl)	2019-10-31	Inhibitory oddziaływania CD40-TRAF6
EP2892529A4 (en)	2016-01-20	USES OF (-) - PERHEXILINE
GB201215942D0 (en)	2012-10-24	Method of treatent
EP2879681A4 (en)	2015-12-23	INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
ZA201503833B (en)	2016-10-26	Method of hemoglobin-f determination